Profile data is unavailable for this security.
About the company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
- Revenue in USD (TTM)12.60m
- Net income in USD-112.64m
- Incorporated2019
- Employees157.00
- LocationIteos Therapeutics Inc321 Arsenal StreetBldg 312, Floor 3, Suite 301WATERTOWN 02472United StatesUSA
- Phone+1 (857) 204-4583
- Fax+1 (302) 655-5049
- Websitehttps://www.iteostherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | 0.00 | -44.60m | 374.48m | 19.00 | -- | -- | -- | -- | -10.38 | -10.38 | 0.00 | -1.56 | 0.00 | -- | -- | 0.00 | -94.31 | -86.84 | -178.23 | -130.46 | -- | -- | -- | -769.76 | -- | -15.46 | 1.74 | -- | -- | -- | -5.33 | -- | -- | -- |
Harrow Inc | 130.19m | -24.41m | 375.55m | 315.00 | -- | 5.28 | -- | 2.88 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
Heron Therapeutics Inc | 127.04m | -110.56m | 375.82m | 126.00 | -- | -- | -- | 2.96 | -0.8695 | -0.8695 | 0.9494 | -0.2261 | 0.5367 | 1.35 | 2.26 | 1,008,286.00 | -46.70 | -53.55 | -71.00 | -71.24 | 48.75 | 52.52 | -87.02 | -170.12 | 1.84 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
Esperion Therapeutics Inc | 116.33m | -209.25m | 376.91m | 240.00 | -- | -- | -- | 3.24 | -2.11 | -2.11 | 1.13 | -3.85 | 0.5128 | 0.8583 | 2.83 | 484,725.00 | -92.23 | -69.45 | -203.94 | -101.81 | 62.81 | -- | -179.87 | -147.44 | 0.867 | -2.85 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
PepGen Inc | 0.00 | -78.63m | 377.90m | 64.00 | -- | 2.57 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Mersana Therapeutics Inc | 36.86m | -171.67m | 383.32m | 123.00 | -- | 10.34 | -- | 10.40 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Lexicon Pharmaceuticals Inc | 1.21m | -177.12m | 384.13m | 285.00 | -- | 4.10 | -- | 318.78 | -0.7975 | -0.7975 | 0.0055 | 0.3802 | 0.0057 | -- | 2.32 | 4,228.07 | -83.60 | -24.41 | -96.00 | -29.01 | 90.95 | 98.49 | -14,698.67 | -84.92 | 5.58 | -13.11 | 0.5166 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
Revance Therapeutics Inc | 234.04m | -323.99m | 384.56m | 534.00 | -- | -- | -- | 1.64 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Anika Therapeutics Inc | 166.66m | -82.67m | 385.10m | 357.00 | -- | 1.79 | -- | 2.31 | -5.64 | -5.64 | 11.37 | 14.48 | 0.5378 | 1.48 | 4.72 | 466,840.30 | -26.68 | -5.41 | -29.48 | -5.87 | 61.85 | 60.70 | -49.60 | -12.60 | 3.76 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
Biomea Fusion Inc | 0.00 | -117.26m | 385.81m | 103.00 | -- | 2.28 | -- | -- | -3.46 | -3.46 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -71.23 | -- | -81.63 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
Tscan Therapeutics Inc | 21.05m | -89.22m | 386.32m | 154.00 | -- | 2.43 | -- | 18.35 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
iTeos Therapeutics Inc | 12.60m | -112.64m | 386.39m | 157.00 | -- | 0.6716 | -- | 30.68 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
Medifast Inc | 897.81m | 67.76m | 386.90m | 634.00 | 5.73 | 1.84 | 4.77 | 0.4309 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
Cartesian Therapeutics Inc | 26.00m | -219.71m | 391.51m | 38.00 | -- | -- | -- | 15.06 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Tourmaline Bio Inc | 0.00 | -42.12m | 397.52m | 44.00 | -- | 1.54 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 31 Dec 2023 | 4.42m | 12.32% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.79m | 7.77% |
EcoR1 Capital, LLCas of 05 Feb 2024 | 1.94m | 5.43% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.45m | 4.06% |
BVF Partners LPas of 31 Dec 2023 | 1.26m | 3.51% |
Citadel Advisors LLCas of 31 Dec 2023 | 1.00m | 2.80% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 997.89k | 2.78% |
Millennium Management LLCas of 31 Dec 2023 | 967.40k | 2.70% |
Saturn V Capital Management LLCas of 31 Dec 2023 | 828.23k | 2.31% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 773.14k | 2.16% |